Skip to Main Content

Abstract Guidelines

Important Dates and Deadlines

January 26, 2021   Abstract Submission Site Opens
January 26, 2021 Call for Workshop and Roundtables Opens
February 26, 2021 Workshop and Roundtables Submission Deadline
April 12, 2021   Abstract Submission Deadline
Mid-April, 2021 Workshop and Roundtables Submitters Receive Accept/Reject Notification
June 21, 2021 Abstract Submitters Receive Accept/Reject Notification
August 2, 2021 Manuscript Submission Deadline (Oral presenters only)
August 4, 2021 Late-breaking Abstract Submission Site Opens
August 18, 2021  Late-breaking Abstract Submission Deadline
September 3, 2021 Late-breaking Abstract Accept/Reject Notification
August 4, 2021 Deadline to Withdraw Accepted Abstract


Abstract Submission Guidelines - Abstract Submissions Are Now Closed

Who is Eligible to Submit?
AUGS Members and non-members are eligible to submit an abstract.

Work submitted for presentation at this meeting may not have been previously published, and may not have been previously presented at another national Obstetrics and Gynecology (SGS, ACOG, AAGL) or Urology (SUFU, AUA) meeting. Please do not submit case reports as they are not permitted and will not be reviewed. Abstracts that have been presented at non-OBGYN or Urology meetings will be accepted for poster presentation only and will not be eligible for prizes. The author must list where and when the research was presented at the bottom of the abstract when submitted. It is acceptable, however, for it to have been presented at an international meeting outside the United States.

Institutional Review Board Waiver
The Institutional Review Board is charged with protecting the rights and welfare of people involved in research. IRB approval or waiver is required for submission of all abstracts. You will be required during online submission to document whether your study has been IRB reviewed. You will be asked to enter the unique IRB identifier number in the space provided on the web form. If approval is waived by an IRB, AUGS must receive a copy of the waiver letter by the submission deadline.

Accessing the Abstract Submission Site

  • The submission site will open on January 26, 2021.
  • There are no restrictions on the number of submissions you may submit or on the number of submissions you may present.
  • The deadline for electronic submissions for abstracts is April 12, 2021 at 11:59 PM, ET.

Submission Criteria

The following are the guidelines for all oral, poster, or video abstract submissions:

Abstract Character Limit

  • Title character limit: None
  • Body character limit: There is a limit of 3300 (including spaces) characters for the text of your submission. You will be advised of your character count usage throughout the submission process as you save and move to the next step.
  • Figures and Tables limit: You may add up to 2 figures and/or tables to your submission. Figures and tables will appear at the end of your abstract, both on the proof and for publication. Figures and tables cannot be placed within the text of the submission. Figures will count up to 560 characters, but the exact count will depend on the size of the figure. For reference, the characters will be deducted from your total character-count once uploaded. Tables count as 50 characters per row, or can be uploaded as a figure.

Abstract Title

  • Please make sure you double-check your title, as it will be published as submitted.
  • Use mixed case for title – do not use all caps or all lowercase. Do not put your title in quotation marks.
  • Titles do not have a character limit.
  • Do not include trial group name in title of abstract.


  • Please consult with your co-authors on how they would like their names to appear. Please enter all authors in the order they should appear in the heading of the abstract. If you (the Contact Author) are not the Presenter on a submission, you will need to provide contact information on the Presenter.
  • All authors and co-authors must disclose any relevant financial relationship(s) at the time of submission.

Responsibilities of the Presenting Author
The first author listed for each abstract serve as the presenting author and as the primary contact for all correspondence regarding the abstract.

The presenting author is responsible for the following:

  • Ensuring that all authors have read the abstract and agreed to be co-authors.
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by AUGS.
  • Obtaining all the conflict of interest disclosure

Abstract Body

Omit all names and geographical references in the body of the abstract. Organize content in sections as follows:

  • Objective: describes the research objective
  • Methods: describes research methodology used
  • Results: summarizes evaluation, including outcome data
  • Conclusions: states the conclusions drawn from results


Disclose any 'relevant' financial relationships in accordance with the ACCME guidelines. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. List any financial interests, assistance, or relationships with companies, supporters, or commercial products related to the research (for example, ownership or partnership; research support; research grants; sponsors; stockholders, etc.). All listed authors/co-authors must complete a disclosure via the online abstract management system.

Presentation Type and Category

  • You will be asked to select the appropriate presentation type for your submission.
  • Some submission types will have only one selection from which to choose.
  • Select the appropriate category using the drop-down menus provided.

Product Name Usage

  • For purposes of blind scoring, institutional names must be omitted whenever possible in the title and body of the abstract.
  • Authors are requested to avoid the use of commercially branded names.
  • If a specific device is only identifiable by its trade name, then this should appear in brackets after a generic description of the device.
  • Should it be necessary to use a trade name, then the trade names of all similar products or those within a class must be used.


  • Carefully check the proof of your abstract. Make sure all special characters and formatting are displaying properly in your proof.
  • If you find errors, return to the appropriate page by clicking on the page name in the left-hand menu to make your corrections.
  • You may return to the online submission site to revise your abstract until April 12, 2021 at 11:59 PM, ET.
  • After this date/time, the submission site will close, and no additional changes/edits can be made.
  • If your abstract contains errors, you may opt to withdraw the abstract.
  • If you have not completed all required sections and detail you will not be able to submit.
  • When all required information is entered, the "Submit" button will appear at the bottom "Proof and Submit" page.


  • After April 12, presenting authors may submit a request to have an abstract withdrawn.
  • To withdraw a submitted abstract, written notification must be sent to
  • This notification must include the title, authors and affiliations (as submitted), the control number, and the name, affiliation, phone, fax and e‐mail of the submitter.
  • We recommend using the summary page as part of this notification.
  • In order for an accepted abstract to be withdrawn and not appear in publications, notification must be received by August 4, 2021.
  • After this date, withdrawals are still accepted but abstracts may still appear in annual meeting materials.

Need Help?

  • For technical assistance regarding the abstract submission site, contact Planstone technical support using the Feedback and Support tab on the right had of the submission screens, or via email at Responses will come between 9:00 am and 5:00 pm Central, Monday through Friday.  
  • For general abstract inquiries, email

Abstract Review

  • After the submission site closes, completed abstracts will be peer reviewed.
  • All abstracts will be blinded for review, meaning the abstracts will be reviewed without knowledge of the author/s, institution/s or disclosure information.
  • Accepted abstracts will be selected as oral, oral poster or poster.

Abstract Acceptance/Rejection Notifications

  • You will be notified electronically of the acceptance/rejection of your abstract June 21, 2021.
  • This notification will include the date and time of session/presentation as well as type of presentation if accepted.
  • Only the presenting author will be notified. It is the responsibility of the presenting author to notify all co-authors.
  • If you do not receive your notification by June 21, 2021, you should contact the

Video Submission Guidelines

Videos and an accompanying abstract describing the objectives of the video must be submitted electronically through the website. The accompanying abstract must be written in English. It should contain a brief description of the Objectives, Methods and clinical relevance of the video submission maximum character is 3300, (same as abstract).

The below criteria must be met for acceptance of video presentation.  

  • Maximum duration: 10 minutes
  • File cannot be above the 500 MB
  • Videos must have English captions or narration   
  • Please ensure that your videos protect patient anonymity and integrity.
  • Acceptable file formats are .mov, .mpg and mp4

PLEASE REMOVE ALL PRODUCT LOGOS/NAMES FROM VIDEO‐ if a video is submitted with the product name/logo included, the video will be disqualified from consideration.

General Information

Embargo Policy

All accepted abstracts submitted to the PFD Week are embargoed until the first day of the meeting. The first author is responsible for conveying this information to all co-authors.

Special Characters and Formatting

If you copy and paste the title and/or body of your submission from your word processor, special characters should transfer, but formatting will not transfer. You can insert special characters and/or formatting tags using the Special Characters Palette. To access the palette, click on the "Special Characters" button located on the Title/Body page.

Content Validity and Fair Balance

Authors are required to prepare fair and balanced presentations that are objective and scientifically rigorous. All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.

Use of Generic versus Trade Names

Abstracts must use scientific or generic names when referring to products.


Accepted abstracts will be considered for the below awards.

  • Best Overall Paper
  • Best Clinical Paper
  • Best Video
  • Best Basic Science Paper
  • Basic Science PhD Award
  • Best Urogynecology Fellow Paper
  • Best Resident Paper